pathway anti her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


Bioz Verified Symbol Roche is a verified supplier
Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche pathway anti her2 neu 4b5 rabbit monoclonal primary antibody
    Pathway Anti Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway anti her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathway anti her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche her2 neu 4b5 rabbit monoclonal primary antibody
    Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche her2 neu 4b5 rabbit monoclonal primary antibody
    Summary of consensus recommendations for <t> HER2 </t> testing in breast cancer.
    Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia"

    Article Title: Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia

    Journal: Cancers

    doi: 10.3390/cancers16132325

    Summary of consensus recommendations for  HER2  testing in breast cancer.
    Figure Legend Snippet: Summary of consensus recommendations for HER2 testing in breast cancer.

    Techniques Used: Control, Sample Prep, Selection, Negative Control, Histopathology, Diagnostic Assay

    Recommended pre-analytical conditions for  HER2  IHC testing [ <xref ref-type= 4 , 5 , 39 , 40 , 41 ]." title="Recommended pre-analytical conditions for HER2 IHC testing [ ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Recommended pre-analytical conditions for HER2 IHC testing [ 4 , 5 , 39 , 40 , 41 ].

    Techniques Used:

    US FDA-approved antibodies utilized for  HER2  IHC testing.
    Figure Legend Snippet: US FDA-approved antibodies utilized for HER2 IHC testing.

    Techniques Used: Staining

    The principles, advantages, and disadvantages of different types of ISH tests [ <xref ref-type= 4 ]." title=" The principles, advantages, and disadvantages of different types of ISH tests [4]. " property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: The principles, advantages, and disadvantages of different types of ISH tests [ 4 ].

    Techniques Used: Labeling, Staining, Light Microscopy, Microscopy, Comparison

    FDA-approved ISH test kits for confirmation of  HER2  gene status.
    Figure Legend Snippet: FDA-approved ISH test kits for confirmation of HER2 gene status.

    Techniques Used:

     HER2  IHC scoring based on ASCO/CAP  HER2  Testing in Breast Cancer 2018 Update [ <xref ref-type= 5 ]." title=" HER2 IHC scoring based on ASCO/CAP ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: HER2 IHC scoring based on ASCO/CAP HER2 Testing in Breast Cancer 2018 Update [ 5 ].

    Techniques Used: Staining, Membrane

    HER2 immunoscoring in breast cancer using the Ventana 4B5 assay. HER2 IHC 0 is shown at ( A ) 5× objective and ( B ) 40× objective (absent to barely perceptible staining in ≤10% of the invasive malignant cells); HER2 IHC 1+ is shown at ( C ) 5× objective and ( D ) 40× objective (faint-to-weak, incomplete membrane staining in >10% of invasive malignant cells); HER2 IHC 2+ is shown at ( E ) 5× objective and ( F ) 40× objective (weak-to-moderate, complete membrane staining in >10% of invasive malignant cells); HER2 IHC 3+ is shown at ( G ) 5× objective and ( H ) 40× objective (circumferential membrane staining that is complete, intense and in >10% of invasive malignant cells, visible at low magnification levels of 4×/5×). HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry.
    Figure Legend Snippet: HER2 immunoscoring in breast cancer using the Ventana 4B5 assay. HER2 IHC 0 is shown at ( A ) 5× objective and ( B ) 40× objective (absent to barely perceptible staining in ≤10% of the invasive malignant cells); HER2 IHC 1+ is shown at ( C ) 5× objective and ( D ) 40× objective (faint-to-weak, incomplete membrane staining in >10% of invasive malignant cells); HER2 IHC 2+ is shown at ( E ) 5× objective and ( F ) 40× objective (weak-to-moderate, complete membrane staining in >10% of invasive malignant cells); HER2 IHC 3+ is shown at ( G ) 5× objective and ( H ) 40× objective (circumferential membrane staining that is complete, intense and in >10% of invasive malignant cells, visible at low magnification levels of 4×/5×). HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry.

    Techniques Used: Staining, Membrane, Immunohistochemistry

    HER2 gene status in breast cancer identified using the dual-probe FISH assay. The sample showed a tumor cell [green circle] with a HER2 /CEP17 ratio of 1.3 and an average HER2 copy number of 2.7, placing the tumor under ISH group 5 (HER2-negative). CEP17: chromosome enumeration probe 17; ISH: in situ hybridization; FISH: fluorescence in situ hybridization; HER2: human epidermal growth factor receptor 2.
    Figure Legend Snippet: HER2 gene status in breast cancer identified using the dual-probe FISH assay. The sample showed a tumor cell [green circle] with a HER2 /CEP17 ratio of 1.3 and an average HER2 copy number of 2.7, placing the tumor under ISH group 5 (HER2-negative). CEP17: chromosome enumeration probe 17; ISH: in situ hybridization; FISH: fluorescence in situ hybridization; HER2: human epidermal growth factor receptor 2.

    Techniques Used: In Situ Hybridization, Fluorescence

    Reporting  HER2  IHC score [ <xref ref-type= 5 , 74 ]." title="Reporting HER2 IHC score [ ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Reporting HER2 IHC score [ 5 , 74 ].

    Techniques Used: Staining, Membrane

    Reporting  HER2  ISH status, according to the ASCO/CAP  HER2  Testing in Breast Cancer 2018 Update [ <xref ref-type= 5 , 66 ]." title="Reporting HER2 ISH status, according to the ASCO/CAP ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Reporting HER2 ISH status, according to the ASCO/CAP HER2 Testing in Breast Cancer 2018 Update [ 5 , 66 ].

    Techniques Used: Amplification

    her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche her2 neu 4b5 rabbit monoclonal primary antibody
    Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    anti her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche anti her2 neu 4b5 rabbit monoclonal primary antibody
    Flow chart. <t>HER2</t> immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC
    Anti Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer"

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    Journal: Diagnostic Pathology

    doi: 10.1186/s13000-024-01508-y

    Flow chart. HER2 immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC
    Figure Legend Snippet: Flow chart. HER2 immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC

    Techniques Used: Immunohistochemistry, In Situ Hybridization, Amplification

    Clinicopathological characteristics of primary tumor from consecutive patients who underwent colorectal and liver metastasis resection for CRC
    Figure Legend Snippet: Clinicopathological characteristics of primary tumor from consecutive patients who underwent colorectal and liver metastasis resection for CRC

    Techniques Used: Amplification, Adjuvant

     HER2  status in colorectal tumor and liver metastasis
    Figure Legend Snippet: HER2 status in colorectal tumor and liver metastasis

    Techniques Used: Amplification

    Illustration of anti-HER2 immunohistochemistry stain. Immunohistochemistry (IHC) score 2 + both on primary ( A ) and metastasis ( B ) in the HER2 amplified case (× 20). Example of IHC stain score 0 on the primary (× 20) ( C ) and on 1 + on the metastasis (× 40) ( D ). Example of IHC stain score 1 + on the primary (× 40) ( E ) and 0 on the metastasis (× 20) ( F )
    Figure Legend Snippet: Illustration of anti-HER2 immunohistochemistry stain. Immunohistochemistry (IHC) score 2 + both on primary ( A ) and metastasis ( B ) in the HER2 amplified case (× 20). Example of IHC stain score 0 on the primary (× 20) ( C ) and on 1 + on the metastasis (× 40) ( D ). Example of IHC stain score 1 + on the primary (× 40) ( E ) and 0 on the metastasis (× 20) ( F )

    Techniques Used: Immunohistochemistry, Staining, Amplification

     HER2  status concordance between primary colorectal tumor and corresponding liver metastasis
    Figure Legend Snippet: HER2 status concordance between primary colorectal tumor and corresponding liver metastasis

    Techniques Used: Amplification

    HER2 immunohistochemistry score among patients with multiple liver metastases . Each metastases of the 24 patients were represented according to their HER2 immunohistochemistry (IHC) score. Eight patients had metachronous metastases (orange) and 16 were diagnosed with synchronous metastases (yellow). Five patients showed a heterogeneous score
    Figure Legend Snippet: HER2 immunohistochemistry score among patients with multiple liver metastases . Each metastases of the 24 patients were represented according to their HER2 immunohistochemistry (IHC) score. Eight patients had metachronous metastases (orange) and 16 were diagnosed with synchronous metastases (yellow). Five patients showed a heterogeneous score

    Techniques Used: Immunohistochemistry

    her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche her2 neu 4b5 rabbit monoclonal primary antibody
    Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    anti her2 primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche anti her2 primary antibody
    Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and <t>HER2</t> ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2
    Anti Her2 Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti her2 primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti her2 primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma"

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    Journal: Cancer Immunology, Immunotherapy : CII

    doi: 10.1007/s00262-024-03721-6

    Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and HER2 ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2
    Figure Legend Snippet: Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and HER2 ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2

    Techniques Used: Immunohistochemistry, Staining

    Clinicopathologic features of responders and non-responders in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population
    Figure Legend Snippet: Clinicopathologic features of responders and non-responders in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Techniques Used: Infection

    Kaplan–Meier curves of progression-free survival according to sex ( A ), histology ( B ), peritoneal metastasis ( C ), HER2 ( D ), baseline PLR ( E ), and baseline MLR ( F ) in the PD-L1 CPS < 5 population. PD-L1, programmed death-ligand 1; CPS, combined positive score; HER2, human epidermal growth factor receptor 2; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio
    Figure Legend Snippet: Kaplan–Meier curves of progression-free survival according to sex ( A ), histology ( B ), peritoneal metastasis ( C ), HER2 ( D ), baseline PLR ( E ), and baseline MLR ( F ) in the PD-L1 CPS < 5 population. PD-L1, programmed death-ligand 1; CPS, combined positive score; HER2, human epidermal growth factor receptor 2; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio

    Techniques Used:

    Univariate and multivariate analyses for progression-free survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population
    Figure Legend Snippet: Univariate and multivariate analyses for progression-free survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Techniques Used: Infection

    Univariate and multivariate analyses for overall survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population
    Figure Legend Snippet: Univariate and multivariate analyses for overall survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Techniques Used: Infection

    pathway anti her2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche pathway anti her2 neu 4b5 rabbit monoclonal primary antibody
    (a) 3,3-diaminobenzidine (DAB) immunohistochemistry (IHC) staining of <t>HER2</t> in the tissue microarray cohort. (b) IHC score by experienced pathologists. The excluded core has been partially blacked out. (c) Comparison of IHC scores between experienced pathologists. PV%: Percentage of positive values.
    Pathway Anti Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway anti her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathway anti her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray"

    Article Title: Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray

    Journal: PLOS ONE

    doi: 10.1371/journal.pone.0303614

    (a) 3,3-diaminobenzidine (DAB) immunohistochemistry (IHC) staining of HER2 in the tissue microarray cohort. (b) IHC score by experienced pathologists. The excluded core has been partially blacked out. (c) Comparison of IHC scores between experienced pathologists. PV%: Percentage of positive values.
    Figure Legend Snippet: (a) 3,3-diaminobenzidine (DAB) immunohistochemistry (IHC) staining of HER2 in the tissue microarray cohort. (b) IHC score by experienced pathologists. The excluded core has been partially blacked out. (c) Comparison of IHC scores between experienced pathologists. PV%: Percentage of positive values.

    Techniques Used: Immunohistochemistry, Microarray, Comparison

    Representative image of TMA-stained HER2 IHC assay by phosphor-integrated dots (PID), including four spots of the negative spot (IHC 0, A2), low expresser (IHC 1+, H5), medium expresser (IHC 2+, G5), and high expresser (IHC 3+, C8). The staining images are 3× digital image magnifications on a Nanozoomer S60.
    Figure Legend Snippet: Representative image of TMA-stained HER2 IHC assay by phosphor-integrated dots (PID), including four spots of the negative spot (IHC 0, A2), low expresser (IHC 1+, H5), medium expresser (IHC 2+, G5), and high expresser (IHC 3+, C8). The staining images are 3× digital image magnifications on a Nanozoomer S60.

    Techniques Used: Staining

    (a) HER2 concordance between DAB and PID re-evaluated based on low HER2 expression. (b) A PID-stained image of tissues judged as having low HER2 expression by DAB staining. The PID value is an integral of the fluorescence intensity of PID in the invasive cancer area. Clear positive signals were detected in all cores, classified as HER2 1+, which is difficult to determine by DAB staining. The staining images are 3× digital image magnifications on a NanoZoomer S60.
    Figure Legend Snippet: (a) HER2 concordance between DAB and PID re-evaluated based on low HER2 expression. (b) A PID-stained image of tissues judged as having low HER2 expression by DAB staining. The PID value is an integral of the fluorescence intensity of PID in the invasive cancer area. Clear positive signals were detected in all cores, classified as HER2 1+, which is difficult to determine by DAB staining. The staining images are 3× digital image magnifications on a NanoZoomer S60.

    Techniques Used: Expressing, Staining, Fluorescence

    This shows the relationship between current HER2 DAB IHC diagnosis and PID IHC score in breast cancer. PID IHC helps classify HER2 positive, low HER2 and HER2 negative. ISH: in situ hybridization.
    Figure Legend Snippet: This shows the relationship between current HER2 DAB IHC diagnosis and PID IHC score in breast cancer. PID IHC helps classify HER2 positive, low HER2 and HER2 negative. ISH: in situ hybridization.

    Techniques Used: In Situ Hybridization

    pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody  (Roche)


    Bioz Verified Symbol Roche is a verified supplier
    Bioz Manufacturer Symbol Roche manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Roche pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody
    Pathway Anti Her 2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars

    Images

    primary antibodies her2  (Vector Laboratories)


    Bioz Verified Symbol Vector Laboratories is a verified supplier
    Bioz Manufacturer Symbol Vector Laboratories manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Vector Laboratories primary antibodies her2
    The histological features of the human samples from which the organoids were derived from.
    Primary Antibodies Her2, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies her2/product/Vector Laboratories
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies her2 - by Bioz Stars, 2024-07
    86/100 stars

    Images

    1) Product Images from "Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models"

    Article Title: Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

    Journal: British Journal of Cancer

    doi: 10.1038/s41416-024-02665-z

    The histological features of the human samples from which the organoids were derived from.
    Figure Legend Snippet: The histological features of the human samples from which the organoids were derived from.

    Techniques Used: Derivative Assay

    A panel of breast cancer organoids ( A ) T-S403276 (HER2 +ve, IHC 2+ and FISH +ve), ( B ) T-S386416 (HER2 equivocal, IHC 2+ and FISH -ve), ( C ) T-S396358 (HER2 -ve), ( D ) T-S396391 (HER2 -ve), ( E ) T-S410880 (HER2 –ve), ( F ) T-S410460 (TNBC) ( G ) T-S358174 (HER2-low)] and their corresponding normal organoids ( H ) N-S410879, ( I ) N-S403275 and ( J ) N-S388920) were treated with an increasing concentration of neratinib for 5 days to obtain dose response curves. Cell proliferation was assessed using 3D cell titre Glo and graph is normalized to control (DMSO + IgG). GraphPad Prism 8 software was used to plot the curves and obtain R-squared and EC50 values. Data presented from 3 independent experiments ( n = 3) with 3 technical replicates; error bars are shown as the median ± range.
    Figure Legend Snippet: A panel of breast cancer organoids ( A ) T-S403276 (HER2 +ve, IHC 2+ and FISH +ve), ( B ) T-S386416 (HER2 equivocal, IHC 2+ and FISH -ve), ( C ) T-S396358 (HER2 -ve), ( D ) T-S396391 (HER2 -ve), ( E ) T-S410880 (HER2 –ve), ( F ) T-S410460 (TNBC) ( G ) T-S358174 (HER2-low)] and their corresponding normal organoids ( H ) N-S410879, ( I ) N-S403275 and ( J ) N-S388920) were treated with an increasing concentration of neratinib for 5 days to obtain dose response curves. Cell proliferation was assessed using 3D cell titre Glo and graph is normalized to control (DMSO + IgG). GraphPad Prism 8 software was used to plot the curves and obtain R-squared and EC50 values. Data presented from 3 independent experiments ( n = 3) with 3 technical replicates; error bars are shown as the median ± range.

    Techniques Used: Concentration Assay, Control, Software

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Roche pathway anti her2 neu 4b5 rabbit monoclonal primary antibody
    Pathway Anti Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway anti her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathway anti her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Roche her2 neu 4b5 rabbit monoclonal primary antibody
    Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Roche anti her2 neu 4b5 rabbit monoclonal primary antibody
    Flow chart. <t>HER2</t> immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC
    Anti Her2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti her2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti her2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Roche anti her2 primary antibody
    Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and <t>HER2</t> ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2
    Anti Her2 Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti her2 primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti her2 primary antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Roche pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody
    Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and <t>HER2</t> ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2
    Pathway Anti Her 2 Neu 4b5 Rabbit Monoclonal Primary Antibody, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody/product/Roche
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pathway anti her 2 neu 4b5 rabbit monoclonal primary antibody - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    86
    Vector Laboratories primary antibodies her2
    The histological features of the human samples from which the organoids were derived from.
    Primary Antibodies Her2, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies her2/product/Vector Laboratories
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies her2 - by Bioz Stars, 2024-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Flow chart. HER2 immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: Flow chart. HER2 immunohistochemistry (IHC) was performed on the 108 paired colorectal tumor – liver metastasis. Two colorectal tumors and two liver metastases were scored 2 + and had their HER2 status assessed by fluorescent in situ hybridization (FISH). One pair (colorectal tumor and liver metastasis) was HER2 amplified and one pair was HER2 non-amplified. In addition, tumor heterogeneity was analyzed for 24 patients with multiple metastases. 85 metastases were scored 0 and 8 were scored 1 + on IHC

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Immunohistochemistry, In Situ Hybridization, Amplification

    Clinicopathological characteristics of primary tumor from consecutive patients who underwent colorectal and liver metastasis resection for CRC

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: Clinicopathological characteristics of primary tumor from consecutive patients who underwent colorectal and liver metastasis resection for CRC

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Amplification, Adjuvant

     HER2  status in colorectal tumor and liver metastasis

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: HER2 status in colorectal tumor and liver metastasis

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Amplification

    Illustration of anti-HER2 immunohistochemistry stain. Immunohistochemistry (IHC) score 2 + both on primary ( A ) and metastasis ( B ) in the HER2 amplified case (× 20). Example of IHC stain score 0 on the primary (× 20) ( C ) and on 1 + on the metastasis (× 40) ( D ). Example of IHC stain score 1 + on the primary (× 40) ( E ) and 0 on the metastasis (× 20) ( F )

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: Illustration of anti-HER2 immunohistochemistry stain. Immunohistochemistry (IHC) score 2 + both on primary ( A ) and metastasis ( B ) in the HER2 amplified case (× 20). Example of IHC stain score 0 on the primary (× 20) ( C ) and on 1 + on the metastasis (× 40) ( D ). Example of IHC stain score 1 + on the primary (× 40) ( E ) and 0 on the metastasis (× 20) ( F )

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Immunohistochemistry, Staining, Amplification

     HER2  status concordance between primary colorectal tumor and corresponding liver metastasis

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: HER2 status concordance between primary colorectal tumor and corresponding liver metastasis

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Amplification

    HER2 immunohistochemistry score among patients with multiple liver metastases . Each metastases of the 24 patients were represented according to their HER2 immunohistochemistry (IHC) score. Eight patients had metachronous metastases (orange) and 16 were diagnosed with synchronous metastases (yellow). Five patients showed a heterogeneous score

    Journal: Diagnostic Pathology

    Article Title: Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer

    doi: 10.1186/s13000-024-01508-y

    Figure Lengend Snippet: HER2 immunohistochemistry score among patients with multiple liver metastases . Each metastases of the 24 patients were represented according to their HER2 immunohistochemistry (IHC) score. Eight patients had metachronous metastases (orange) and 16 were diagnosed with synchronous metastases (yellow). Five patients showed a heterogeneous score

    Article Snippet: Immunostaining was performed on the Ventana Benchmark automatic immunostainer® (Roche diagnostics, Meylan, France), using a VENTANA anti-HER2/neu® (4B5) rabbit monoclonal primary antibody, according to the manufacturer’s instruction.

    Techniques: Immunohistochemistry

    Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and HER2 ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    doi: 10.1007/s00262-024-03721-6

    Figure Lengend Snippet: Representative immunohistochemistry staining images (20×) of the PD-L1 ( A ), EBER ( B ), and HER2 ( C ) in the enrolled patients. PD-L1, programmed death-ligand 1; CPS, combined positive score; EBER, EBV-encoded RNA; HER2, human epidermal growth factor receptor 2

    Article Snippet: HER2 status was detected by immunohistochemistry (IHC) staining with a monoclonal anti-HER2 primary antibody (4B5, VENTANA, USA) and fluorescence in situ hybridization (FISH) using a Jin Pujia GP HER2 probe kit (Beijing Jin Pujia Medical Technology Company Limited, Beijing, China).

    Techniques: Immunohistochemistry, Staining

    Clinicopathologic features of responders and non-responders in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    doi: 10.1007/s00262-024-03721-6

    Figure Lengend Snippet: Clinicopathologic features of responders and non-responders in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Article Snippet: HER2 status was detected by immunohistochemistry (IHC) staining with a monoclonal anti-HER2 primary antibody (4B5, VENTANA, USA) and fluorescence in situ hybridization (FISH) using a Jin Pujia GP HER2 probe kit (Beijing Jin Pujia Medical Technology Company Limited, Beijing, China).

    Techniques: Infection

    Kaplan–Meier curves of progression-free survival according to sex ( A ), histology ( B ), peritoneal metastasis ( C ), HER2 ( D ), baseline PLR ( E ), and baseline MLR ( F ) in the PD-L1 CPS < 5 population. PD-L1, programmed death-ligand 1; CPS, combined positive score; HER2, human epidermal growth factor receptor 2; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    doi: 10.1007/s00262-024-03721-6

    Figure Lengend Snippet: Kaplan–Meier curves of progression-free survival according to sex ( A ), histology ( B ), peritoneal metastasis ( C ), HER2 ( D ), baseline PLR ( E ), and baseline MLR ( F ) in the PD-L1 CPS < 5 population. PD-L1, programmed death-ligand 1; CPS, combined positive score; HER2, human epidermal growth factor receptor 2; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio

    Article Snippet: HER2 status was detected by immunohistochemistry (IHC) staining with a monoclonal anti-HER2 primary antibody (4B5, VENTANA, USA) and fluorescence in situ hybridization (FISH) using a Jin Pujia GP HER2 probe kit (Beijing Jin Pujia Medical Technology Company Limited, Beijing, China).

    Techniques:

    Univariate and multivariate analyses for progression-free survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    doi: 10.1007/s00262-024-03721-6

    Figure Lengend Snippet: Univariate and multivariate analyses for progression-free survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Article Snippet: HER2 status was detected by immunohistochemistry (IHC) staining with a monoclonal anti-HER2 primary antibody (4B5, VENTANA, USA) and fluorescence in situ hybridization (FISH) using a Jin Pujia GP HER2 probe kit (Beijing Jin Pujia Medical Technology Company Limited, Beijing, China).

    Techniques: Infection

    Univariate and multivariate analyses for overall survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Journal: Cancer Immunology, Immunotherapy : CII

    Article Title: Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma

    doi: 10.1007/s00262-024-03721-6

    Figure Lengend Snippet: Univariate and multivariate analyses for overall survival in the PD-L1 CPS \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ <$$\end{document} < 5 population

    Article Snippet: HER2 status was detected by immunohistochemistry (IHC) staining with a monoclonal anti-HER2 primary antibody (4B5, VENTANA, USA) and fluorescence in situ hybridization (FISH) using a Jin Pujia GP HER2 probe kit (Beijing Jin Pujia Medical Technology Company Limited, Beijing, China).

    Techniques: Infection

    The histological features of the human samples from which the organoids were derived from.

    Journal: British Journal of Cancer

    Article Title: Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

    doi: 10.1038/s41416-024-02665-z

    Figure Lengend Snippet: The histological features of the human samples from which the organoids were derived from.

    Article Snippet: After a washing step and blocking the slides with horse serum (Vector laboratories) primary antibodies HER2, 21D3, Cell signalling at a concentration of 1.150 were applied overnight at 4 °C.

    Techniques: Derivative Assay

    A panel of breast cancer organoids ( A ) T-S403276 (HER2 +ve, IHC 2+ and FISH +ve), ( B ) T-S386416 (HER2 equivocal, IHC 2+ and FISH -ve), ( C ) T-S396358 (HER2 -ve), ( D ) T-S396391 (HER2 -ve), ( E ) T-S410880 (HER2 –ve), ( F ) T-S410460 (TNBC) ( G ) T-S358174 (HER2-low)] and their corresponding normal organoids ( H ) N-S410879, ( I ) N-S403275 and ( J ) N-S388920) were treated with an increasing concentration of neratinib for 5 days to obtain dose response curves. Cell proliferation was assessed using 3D cell titre Glo and graph is normalized to control (DMSO + IgG). GraphPad Prism 8 software was used to plot the curves and obtain R-squared and EC50 values. Data presented from 3 independent experiments ( n = 3) with 3 technical replicates; error bars are shown as the median ± range.

    Journal: British Journal of Cancer

    Article Title: Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

    doi: 10.1038/s41416-024-02665-z

    Figure Lengend Snippet: A panel of breast cancer organoids ( A ) T-S403276 (HER2 +ve, IHC 2+ and FISH +ve), ( B ) T-S386416 (HER2 equivocal, IHC 2+ and FISH -ve), ( C ) T-S396358 (HER2 -ve), ( D ) T-S396391 (HER2 -ve), ( E ) T-S410880 (HER2 –ve), ( F ) T-S410460 (TNBC) ( G ) T-S358174 (HER2-low)] and their corresponding normal organoids ( H ) N-S410879, ( I ) N-S403275 and ( J ) N-S388920) were treated with an increasing concentration of neratinib for 5 days to obtain dose response curves. Cell proliferation was assessed using 3D cell titre Glo and graph is normalized to control (DMSO + IgG). GraphPad Prism 8 software was used to plot the curves and obtain R-squared and EC50 values. Data presented from 3 independent experiments ( n = 3) with 3 technical replicates; error bars are shown as the median ± range.

    Article Snippet: After a washing step and blocking the slides with horse serum (Vector laboratories) primary antibodies HER2, 21D3, Cell signalling at a concentration of 1.150 were applied overnight at 4 °C.

    Techniques: Concentration Assay, Control, Software